

CORRECTION

Open Access



# Correction to: Clinical feasibility of umbilical cord tissue-derived mesenchymal stem cells in the treatment of multiple sclerosis

Neil H. Riordan<sup>1,2\*</sup>, Isabela Morales<sup>2</sup>, Giselle Fernández<sup>1</sup>, Nicole Allen<sup>3</sup>, Neal E. Fearnot<sup>3</sup>, Michael E. Leckrone<sup>4</sup>, Dedra Jones Markovich<sup>3</sup>, Darla Mansfield<sup>3</sup>, Dorita Avila<sup>2</sup>, Amit N. Patel<sup>5</sup>, Santosh Kesari<sup>6</sup> and Jorge Paz Rodriguez<sup>1</sup>

## Correction to: *J Transl Med* (2018) 16:57

<https://doi.org/10.1186/s12967-018-1433-7>

The original publication of this article [1] contained 2 errors in the funding and discussion section. In this correction article the incorrect and correct information is published for clarification.

The following sentence in the Funding section, “**The study sponsor had no role in the design of this study, its execution, analysis, interpretation of the data, writing, or decision to submit results.**” should read “**The study sponsor had a role in the design of this study, its execution, analysis as JPR is a shareholder of Translational Biosciences, MediStem Panama, and the Stem Cell Institute.**”

The following sentence in the Discussion last paragraph, “**The small sample size is the most significant limitation of this study in that it may impact the statistical significance of the results.**” in the limitations paragraph should read instead “**The small sample size is the most significant limitation of this study in that it may impact the statistical significance of the results, when considering the suitability of a t-test on a small sample size.**”

The original article can be found online at <https://doi.org/10.1186/s12967-018-1433-7>.

\*Correspondence: [nhriordan@gmail.com](mailto:nhriordan@gmail.com)

<sup>1</sup> Stem Cell Institute, Panama City, Panama

Full list of author information is available at the end of the article

## Author details

<sup>1</sup>Stem Cell Institute, Panama City, Panama. <sup>2</sup>MediStem Panama Inc., Clayton, City of Knowledge, Panama City, Panama. <sup>3</sup>Cook Advanced Technologies, West Lafayette, IN, USA. <sup>4</sup>Cook Medical Technologies, Bloomington, IN, USA. <sup>5</sup>Department of Surgery, University of Miami School of Medicine, Miami, FL, USA. <sup>6</sup>Department of Translational Neurosciences and Neurotherapeutics, John Wayne Cancer Institute and Pacific Neuroscience Institute, Santa Monica, CA, USA.

Published online: 10 May 2021

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

## Reference

1. Riordan NH, Morales I, Fernández G, Allen N, Fearnot NE, Leckrone ME, Markovich DJ, Mansfield D, Avila D, Patel AN, Kesari S, Rodriguez JP. Clinical feasibility of umbilical cord tissue-derived mesenchymal stem cells in the treatment of multiple sclerosis. *J Transl Med*. 2018;16:57. <https://doi.org/10.1186/s12967-018-1433-7>.

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

